company background image
CMRX logo

Chimerix NasdaqGM:CMRX Stock Report

Last Price

US$8.46

Market Cap

US$760.9m

7D

0.4%

1Y

635.7%

Updated

16 Mar, 2025

Data

Company Financials +

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Chimerix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Chimerix
Historical stock prices
Current Share PriceUS$8.46
52 Week HighUS$8.48
52 Week LowUS$0.75
Beta0.32
1 Month Change93.15%
3 Month Change190.72%
1 Year Change635.65%
3 Year Change59.62%
5 Year Change555.81%
Change since IPO-54.98%

Recent News & Updates

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Feb 20

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 11

Recent updates

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Feb 20

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 11

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Jul 16
We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Aug 23

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Jul 20
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Jun 06

Chimerix: Searching For Clarity

Jan 05

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Dec 24
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Sep 16
Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Jun 08
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Jun 04

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

May 13
Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow

May 08

Shareholder Returns

CMRXUS BiotechsUS Market
7D0.4%-0.9%-2.2%
1Y635.7%-5.0%9.6%

Return vs Industry: CMRX exceeded the US Biotechs industry which returned -5.2% over the past year.

Return vs Market: CMRX exceeded the US Market which returned 9.5% over the past year.

Price Volatility

Is CMRX's price volatile compared to industry and market?
CMRX volatility
CMRX Average Weekly Movement22.2%
Biotechs Industry Average Movement10.7%
Market Average Movement6.4%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.4%

Stable Share Price: CMRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CMRX's weekly volatility has decreased from 34% to 22% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200072Mike Andriolewww.chimerix.com

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Chimerix, Inc. Fundamentals Summary

How do Chimerix's earnings and revenue compare to its market cap?
CMRX fundamental statistics
Market capUS$760.86m
Earnings (TTM)-US$83.59m
Revenue (TTM)US$159.00k

4,785x

P/S Ratio

-9.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMRX income statement (TTM)
RevenueUS$159.00k
Cost of RevenueUS$73.55m
Gross Profit-US$73.39m
Other ExpensesUS$10.21m
Earnings-US$83.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.93
Gross Margin-46,154.72%
Net Profit Margin-52,574.84%
Debt/Equity Ratio0%

How did CMRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 01:38
End of Day Share Price 2025/03/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chimerix, Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Jonathan AschoffBrean Capital
Ritu BaralCanaccord Genuity